Literature DB >> 30767695

Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology.

Rui Pedro Moura1, Cláudia Martins2,3,4, Soraia Pinto2,3, Flávia Sousa1,2,3,4, Bruno Sarmento1,2,3.   

Abstract

INTRODUCTION: The blood-brain barrier (BBB) is a highly limiting barrier that prevents the brain from contacting with several circulating molecules, including harmful agents. However, certain systemic nutrients and macromolecules are able to cross the BBB and reach the brain parenchyma, involving the interaction with multiple receptors and/or transporters at the BBB surface. Nanotechnology allows the creation of drug vehicles, functionalized with targeting ligands for binding specific BBB receptors and/or transporters, hence triggering the transport through this biobarrier. AREAS COVERED: This review focuses the BBB receptors/transporters to be exploited in regard to their overall structure and biologic function, as well as their role in the development of strategies envisaging drug delivery to the brain. Then, the interplay between the targeting of these BBB receptors/transporters and nanotechnology is explored, as they can increase by several-fold the effectiveness of brain-targeted therapies. EXPERT OPINION: Nanomedicine may be particularly useful in brain drug delivery, mainly due to the possibility of functionalizing nanoparticles to target specific receptors/transporters. Since the BBB is endowed with numerous receptors and transporters responsible for regulating the proper metabolic activity of the brain, their targeting can be a promising bypass strategy to circumvent the hurdle that the BBB represents for brain drug delivery.

Keywords:  Blood-brain barrier; central nervous system; nanotechnology; receptor-mediated transcytosis; receptors; transporters

Mesh:

Substances:

Year:  2019        PMID: 30767695     DOI: 10.1080/17425247.2019.1583205

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  17 in total

1.  Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.

Authors:  Hsueh-Yuan Chang; Shengjia Wu; Ekram Ahmed Chowdhury; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-29       Impact factor: 2.745

2.  Basic physiology of the blood-brain barrier in health and disease: a brief overview.

Authors:  Mehmet Kaya; Bulent Ahishali
Journal:  Tissue Barriers       Date:  2020-11-15

Review 3.  Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation.

Authors:  Samo Ribarič
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 4.  Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery.

Authors:  Sara Bernardo-Castro; João André Sousa; Ana Brás; Carla Cecília; Bruno Rodrigues; Luciano Almendra; Cristina Machado; Gustavo Santo; Fernando Silva; Lino Ferreira; Isabel Santana; João Sargento-Freitas
Journal:  Front Neurol       Date:  2020-12-09       Impact factor: 4.003

Review 5.  Natural Polysaccharide Carriers in Brain Delivery: Challenge and Perspective.

Authors:  Manuela Curcio; Giuseppe Cirillo; Jourdin R C Rouaen; Federica Saletta; Fiore Pasquale Nicoletta; Orazio Vittorio; Francesca Iemma
Journal:  Pharmaceutics       Date:  2020-12-06       Impact factor: 6.321

Review 6.  Exosomal delivery of therapeutic modulators through the blood-brain barrier; promise and pitfalls.

Authors:  Reza Rahbarghazi; Emel Sokullu; Morteza Heidarzadeh; Yasemin Gürsoy-Özdemir; Mehmet Kaya; Aysan Eslami Abriz; Amir Zarebkohan
Journal:  Cell Biosci       Date:  2021-07-22       Impact factor: 7.133

Review 7.  Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies.

Authors:  Maria Inês Teixeira; Maria Helena Amaral; Paulo C Costa; Carla M Lopes; Dimitrios A Lamprou
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

Review 8.  Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics.

Authors:  Shahryar Shakeri; Milad Ashrafizadeh; Ali Zarrabi; Rasoul Roghanian; Elham Ghasemipour Afshar; Abbas Pardakhty; Reza Mohammadinejad; Anuj Kumar; Vijay Kumar Thakur
Journal:  Biomedicines       Date:  2020-01-13

Review 9.  Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?

Authors:  Yan-Mei Qiu; Chun-Lin Zhang; An-Qi Chen; Hai-Ling Wang; Yi-Fan Zhou; Ya-Nan Li; Bo Hu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

10.  Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice.

Authors:  Jia Ouyang; Yu Jiang; Chao Deng; Zhiyuan Zhong; Qing Lan
Journal:  Int J Nanomedicine       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.